Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies

Mark R. Stein, Robert P. Nelson, Joseph A. Church, Richard L. Wasserman, Michael Borte, Christiane Vermylen, Johann Bichler

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Purpose: The present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L l-proline (Privigen®), in patients with primary immunodeficiency disease. Materials and Methods: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen® infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. Results: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg-1 min-1). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9% of infusions, either during or within 72 h after infusion end. Conclusion: Privigen® is well tolerated and effective for the treatment of primary immunodeficiency.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalJournal of Clinical Immunology
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Intravenous Immunoglobulins
Safety
Bacterial Infections
Common Variable Immunodeficiency
Intravenous Infusions
Proline
Immunoglobulin G
Infection
Serum
Pharmaceutical Preparations
Therapeutics

Keywords

  • Common variable immunodeficiency (CVID)
  • Intravenous immunoglobulin (IVIG)
  • Primary immunodeficiency (PID)
  • X-linked agammaglobulinemia (XLA)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. / Stein, Mark R.; Nelson, Robert P.; Church, Joseph A.; Wasserman, Richard L.; Borte, Michael; Vermylen, Christiane; Bichler, Johann.

In: Journal of Clinical Immunology, Vol. 29, No. 1, 01.01.2009, p. 137-144.

Research output: Contribution to journalArticle

Stein, Mark R. ; Nelson, Robert P. ; Church, Joseph A. ; Wasserman, Richard L. ; Borte, Michael ; Vermylen, Christiane ; Bichler, Johann. / Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. In: Journal of Clinical Immunology. 2009 ; Vol. 29, No. 1. pp. 137-144.
@article{0877a9b11ae04cf4aae32f64c6022d7e,
title = "Safety and efficacy of Privigen{\circledR}, a novel 10{\%} liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies",
abstract = "Purpose: The present study was designed to evaluate the efficacy and safety of a novel, 10{\%} liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L l-proline (Privigen{\circledR}), in patients with primary immunodeficiency disease. Materials and Methods: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen{\circledR} infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. Results: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg-1 min-1). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9{\%} of infusions, either during or within 72 h after infusion end. Conclusion: Privigen{\circledR} is well tolerated and effective for the treatment of primary immunodeficiency.",
keywords = "Common variable immunodeficiency (CVID), Intravenous immunoglobulin (IVIG), Primary immunodeficiency (PID), X-linked agammaglobulinemia (XLA)",
author = "Stein, {Mark R.} and Nelson, {Robert P.} and Church, {Joseph A.} and Wasserman, {Richard L.} and Michael Borte and Christiane Vermylen and Johann Bichler",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s10875-008-9231-2",
language = "English (US)",
volume = "29",
pages = "137--144",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies

AU - Stein, Mark R.

AU - Nelson, Robert P.

AU - Church, Joseph A.

AU - Wasserman, Richard L.

AU - Borte, Michael

AU - Vermylen, Christiane

AU - Bichler, Johann

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose: The present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L l-proline (Privigen®), in patients with primary immunodeficiency disease. Materials and Methods: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen® infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. Results: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg-1 min-1). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9% of infusions, either during or within 72 h after infusion end. Conclusion: Privigen® is well tolerated and effective for the treatment of primary immunodeficiency.

AB - Purpose: The present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L l-proline (Privigen®), in patients with primary immunodeficiency disease. Materials and Methods: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen® infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. Results: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg-1 min-1). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9% of infusions, either during or within 72 h after infusion end. Conclusion: Privigen® is well tolerated and effective for the treatment of primary immunodeficiency.

KW - Common variable immunodeficiency (CVID)

KW - Intravenous immunoglobulin (IVIG)

KW - Primary immunodeficiency (PID)

KW - X-linked agammaglobulinemia (XLA)

UR - http://www.scopus.com/inward/record.url?scp=59549096424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59549096424&partnerID=8YFLogxK

U2 - 10.1007/s10875-008-9231-2

DO - 10.1007/s10875-008-9231-2

M3 - Article

C2 - 18814020

AN - SCOPUS:59549096424

VL - 29

SP - 137

EP - 144

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 1

ER -